Assess the cumulative incidence of severe (III-IV) aGVHD after low-dose cyclophosphamide or CNI is used to after gDLI. Evaluate the overall survival rate (OS), non recurrent mortality rate (NRM), and recurrence rate (CIR) of two groups of patients; The complete response rate (CR) and partial response rate (PR) of patients with morphological/extramedullary recurrence, as well as the complete response rate and MRD response rate of patients with molecular recurrence. The incidence of adverse events such as infection, hemorrhagic cystitis, and cardiac events in two groups.
Patients with malignant hematological diseases undergo haploid/sibling incomplete matching/unrelated donor transplantation;
Recurrence after transplantation (morphological, extramedullary, or molecular recurrence);
Plan to administer granulocyte colony-stimulating factor mobilization donor lymphocyte infusion (gDLI) for treatment;
No age, gender, or race restrictions;
Siblings of matched donor transplant;
Patients with other malignant tumors that require treatment;
There are active infections, such as hepatitis B, hepatitis C, tuberculosis, etc;
HIV serological reaction was positive;